Conversations in CV Risk Assessment
Our approach to cardiovascular risk assessment is evolving, and it’s time to look beyond traditional markers like LDL and blood pressure. That’s why our Conversations in CV Risk Assessment collection brings together leading experts in cardiology, nephrology, endocrinology, and primary care to explore albuminuria and eGFR. These often-overlooked tools can not only uncover hidden cardiovascular risk long before symptoms appear, but they can also guide proactive, evidence-based interventions to prevent heart failure, stroke, and other serious outcomes.
Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Unseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Conversations in CV Risk AssessmentUnseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
Predicting the Heart’s Future: Albuminuria as a CV Warning Sign
Conversations in CV Risk AssessmentPredicting the Heart’s Future: Albuminuria as a CV Warning Sign
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Heart Failure and Albuminuria: Connecting the Dots
Conversations in CV Risk AssessmentHeart Failure and Albuminuria: Connecting the Dots
Jennifer Caudle, DO, FACOFP
Robert J. Mentz, MD, FHFSA, FACC
Bridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Conversations in CV Risk AssessmentBridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
The Risk Equation: Combining uACR and eGFR for CV Prediction
Conversations in CV Risk AssessmentThe Risk Equation: Combining uACR and eGFR for CV Prediction
Matthew Sorrentino, MD
Ashish Verma, MBBS
- advertisement
